Cantitate/Preț
Produs

Novel Designs of Early Phase Trials for Cancer Therapeutics

Editat de Shivaani Kummar, Chris Takimoto
en Limba Engleză Paperback – 25 mai 2018
Novel Designs of Early Phase Trials for Cancer Therapeutics provides a comprehensive review by leaders in the field of the process of drug development, the integration of molecular profiling, the changes in early phase trial designs, and endpoints to optimally develop a new generation of cancer therapeutics. The book discusses topics such as statistical perspectives on cohort expansions, the role and application of molecular profiling and how to integrate biomarkers in early phase trials. Additionally, it discusses how to incorporate patient reported outcomes in phase one trials.
This book is a valuable resource for medical oncologists, basic and translational biomedical scientists, and trainees in oncology and pharmacology who are interested in learning how to improve their research by using early phase trials.


  • Brings a comprehensive review and recommendations for new clinical trial designs for modern cancer therapeutics
  • Provides the reader with a better understanding on how to design and implement early phase oncology trials
  • Presents a better and updated understanding of the process of developing new treatments for cancer, the exciting scientific advances and how they are informing drug development
Citește tot Restrânge

Preț: 71778 lei

Preț vechi: 75556 lei
-5% Nou

Puncte Express: 1077

Preț estimativ în valută:
13743 14311$ 11403£

Carte tipărită la comandă

Livrare economică 07-21 februarie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780128125120
ISBN-10: 0128125128
Pagini: 234
Dimensiuni: 191 x 235 mm
Greutate: 0.48 kg
Editura: ELSEVIER SCIENCE

Public țintă

medical oncologists; translational biomedical researchers; graduate students on oncology, pharmacology, regulatory affairs and patient reported outcomes

Cuprins

Introduction: Changing landscape of phase I trials1. Phase I trial designs: Past, Present, and Future2. Statistical perspectives on cohort expansions in early phase trials3. Determining the optimal dose and schedule4. Conducting large phase I trials with multiple expansion cohorts5. Role and application of molecular profiling in early phase trials6. Novel trial designs for immunotherapies7. Designing trials for cell based therapies8. Evaluating novel drug combinations in early phase trials9. Integrating biomarkers in early phase trials: developing the evidence base for ‘actionable’ biomarkers10. Novel imaging endpoints in early phase trials11. Developing a novel agent: the regulatory process perspective12. Conducting proof of concept phase I trials-Regulatory Implications13. Efficacy endpoints in early phase trials14. Incorporation of Patient Reported Outcomes in early phase trials